Paper19920100
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
Mittendorf EA and 12 others. Clin Cancer Res, 2009. Cited by 286 papers, by iCite.
Cite this record
ConductScience Library. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Papers, record 19920100. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19920100
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Breast Neoplasms | Major topic |
| Neoadjuvant Therapy | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Anthracyclines | |
| Antibodies, Monoclonal, Humanized | |
| Antineoplastic Agents | |
| Cell Line, Tumor | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Middle Aged | |
| Recurrence | |
| Taxoids | |
| Trastuzumab | |
| Treatment Outcome |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K23 CA121994 | NCI NIH HHS | United States | K23CA121994 | PubMed and NIH | NIH RePORTER |
| K99 CA133244 | NCI NIH HHS | United States | K99CA133244 | PubMed and NIH | NIH RePORTER |
| 1K99CA133244-01 | NCI NIH HHS | United States | K99CA133244 | PubMed and NIH | NIH RePORTER |
| 1K23CA121994-01 | NCI NIH HHS | United States | K23CA121994 | PubMed and NIH | NIH RePORTER |
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16809727 | HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16809727 | PubMed |
| 2 | 19060928 | Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. | Oncogene | 2009 | https://conductscience.org/library/papers/19060928 | PubMed |
| 3 | 19596702 | Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. | Ann Oncol | 2009 | https://conductscience.org/library/papers/19596702 | PubMed |
| 4 | 9256133 | HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. | J Clin Oncol | 1997 | https://conductscience.org/library/papers/9256133 | PubMed |
| 5 | 2470152 | Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. | Science | 1989 | https://conductscience.org/library/papers/2470152 | PubMed |
| 6 | 16739334 | HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. | Anticancer Res | 2006 | https://conductscience.org/library/papers/16739334 | PubMed |
| 7 | 11916237 | Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. | Clin Cancer Res | 2001 | https://conductscience.org/library/papers/11916237 | PubMed |
| 8 | 7647336 | MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. | Breast Cancer Res Treat | 1995 | https://conductscience.org/library/papers/7647336 | PubMed |
| 9 | 12048273 | Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. | J Natl Cancer Inst | 2002 | https://conductscience.org/library/papers/12048273 | PubMed |
| 10 | 1967301 | Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. | J Clin Oncol | 1990 | https://conductscience.org/library/papers/1967301 | PubMed |
| 11 | 17159189 | American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17159189 | PubMed |
| 12 | 16236738 | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16236738 | PubMed |
| 13 | 10561337 | Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10561337 | PubMed |
| 14 | 18757266 | Trastuzumab administration associated with change in HER2 status. | Clin Breast Cancer | 2008 | https://conductscience.org/library/papers/18757266 | PubMed |
| 15 | 12506169 | Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12506169 | PubMed |
| 16 | 3798106 | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. | Science | 1987 | https://conductscience.org/library/papers/3798106 | PubMed |
| 17 | 10080586 | Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10080586 | PubMed |
| 18 | 15738535 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15738535 | PubMed |
| 19 | 16166438 | Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/16166438 | PubMed |
| 20 | 16184453 | Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. | Breast Cancer Res Treat | 2005 | https://conductscience.org/library/papers/16184453 | PubMed |
Cited by172
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 286 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42724786 | Residual disease in HER2-positive early breast cancer: are we escalating the RIGHT patients to T-DM1 or T-DXd? | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724786 | PubMed |
| 42311837 | HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies. | Breast Cancer (Dove Med Press) | 2026 | https://conductscience.org/library/papers/42311837 | PubMed |
| 41899536 | Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899536 | PubMed |
| 41642399 | Breast Cancer Brain Metastases: Current Understanding and Future Directions. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/41642399 | PubMed |
| 41604118 | Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer. | Int J Clin Oncol | 2026 | https://conductscience.org/library/papers/41604118 | PubMed |
| 41462365 | Development and multicenter external validation of an intratumoral and peritumoral ultrasound-based radiomics model for preoperative prediction of HER2 status in IHC 2 + breast cancer. | Eur J Med Res | 2025 | https://conductscience.org/library/papers/41462365 | PubMed |
| 41402487 | Antibody-lectin chimeras for glyco-immune checkpoint blockade. | Nat Biotechnol | 2026 | https://conductscience.org/library/papers/41402487 | PubMed |
| 41155800 | The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41155800 | PubMed |
| 41113985 | Therapeutic challenges in HER2-targeted antibody therapies: trastuzumab and its ADC derivatives in breast cancer. | Am J Cancer Res | 2025 | https://conductscience.org/library/papers/41113985 | PubMed |
| 40930104 | Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA. | Cell Genom | 2025 | https://conductscience.org/library/papers/40930104 | PubMed |
| 40910883 | Evaluating Breast Cancer Intravoxel Incoherent Motion MRI Biomarkers across Software Platforms. | Radiol Imaging Cancer | 2025 | https://conductscience.org/library/papers/40910883 | PubMed |
| 40437301 | Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40437301 | PubMed |
| 40265417 | Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody. | Antibodies (Basel) | 2025 | https://conductscience.org/library/papers/40265417 | PubMed |
| 40148195 | Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy. | Breast | 2025 | https://conductscience.org/library/papers/40148195 | PubMed |
| 40114960 | Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC). | Transl Lung Cancer Res | 2025 | https://conductscience.org/library/papers/40114960 | PubMed |
| 39786525 | Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing. | Curr Oncol Rep | 2025 | https://conductscience.org/library/papers/39786525 | PubMed |
| 39687980 | Breast biomarkers evolution between primary and distant metastasis: incidence and significance. | Histopathology | 2025 | https://conductscience.org/library/papers/39687980 | PubMed |
| 39473863 | Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature. | World J Clin Oncol | 2024 | https://conductscience.org/library/papers/39473863 | PubMed |
| 39468041 | Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab. | NPJ Breast Cancer | 2024 | https://conductscience.org/library/papers/39468041 | PubMed |
| 39350043 | Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study. | BMC Cancer | 2024 | https://conductscience.org/library/papers/39350043 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19920100
GET https://conductscience.org/api/papers/v1/19920100/references?page=2